Adolor IND (correction)
This article was originally published in The Pink Sheet Daily
Executive Summary
Potential convulsant activity is an issue for the Delta opioid receptor class, but FDA has not asked Adolor to examine the potential activity as part of its clinical hold on the IND of the firm's compound ADL5859. In a Jan. 30 1article, "The Pink Sheet" DAILY incorrectly reported that FDA had asked for information on that as part of the clinical hold